CD86

Cluster of Differentiation 86 (also known as CD86 and B7-2) is a protein expressed on antigen-presenting cells that provides costimulatory signals necessary for T cell activation and survival. It is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD86 works in tandem with CD80 to prime T cells.

The CD86 gene encodes a type I membrane protein that is a member of the immunoglobulin superfamily.Alternative splicing results in two transcript variants encoding different isoforms. Additional transcript variants have been described, but their full-length sequences have not been determined.

See also

  • Cluster of differentiation
  • CD80
  • CD28
  • CTLA-4
  • List of human clusters of differentiation for a list of CD molecules
  • References

    Further reading

    This article incorporates text from the United States National Library of Medicine, which is in the public domain.


    Podcasts:

    PLAYLIST TIME:

    Latest News for: b7.2

    Edit

    Take note: 4G takes E Ink scribbling mobile with Bigme B7 launch

    New Atlas 16 Apr 2025
    The latest to join the party comes in the shape of a color E Ink tablet called the Bigme B7. The B7 was originally outed on Chinese social media last month, and has now appeared on Bigme's global store in preparation for global release ... Bigme B7.
    Edit

    What Are B7 Stud Bolts? Properties, Applications, And Benefits

    MENA FN 14 Apr 2025
    (MENAFN - Market Press Release) April 14, 2025 12.34 am - Delta Fitt Inc is a trusted B7 stud bolts supplier, offering precision-engineered fasteners for various industrial applications. In ... .
    Edit

    BriaCell's Subsidiary, BriaPro, Develops Novel Antibodies to Anti-Cancer Target B7-H3

    Nasdaq Globe Newswire 10 Apr 2025
    (“BriaPro”), are pleased to announce that BriaPro is developing novel, high affinity antibodies to B7-H3, a key player in cancer ...
    Edit

    Opening of Trading on April 7 2025-DIRECT FINAN B7 (Direct Finance of Direct Group 2006 Ltd)

    Public Technologies 06 Apr 2025
    ). The text version of this document is not available ... Disclaimer ... (noodl. 123497820) .
    Edit

    Mabwell Announces NMPA Approval to Initiate Clinical Trial of novel B7-H3-targeting ADC for Advanced Solid Tumors in Combination with PD-1 Inhibitor

    PR Newswire 02 Apr 2025
    SHANGHAI, April 2, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its novel B7-H3-targeting ADC (R&D code ... For more information, please visit www.mabwell.com/en ... 440k+ ... 9k+ ... .
    • 1
    ×